Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Updated June 2026 · ClinicalTrials.gov

H. Lee Moffitt Cancer Center and Research Institute

Reviewed by TrialFinderData Editorial Team · Updated

8 clinical trials · 8 recruiting · OTHER

H. Lee Moffitt Cancer Center and Research Institute has 8 clinical trials registered on ClinicalTrials.gov, with 8 actively recruiting participants. The trials listed below cover 16 conditions across the phases listed in the sidebar. Always discuss any specific trial with your physician before contacting a study site.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About H. Lee Moffitt Cancer Center and Research Institute\'s Trial Portfolio

H. Lee Moffitt Cancer Center and Research Institute is a non-industry sponsor (academic medical center, hospital, foundation, or research network). Non-industry sponsors often investigate novel approaches, rare conditions, and behavioral or surgical interventions that commercial sponsors may not prioritize.

8 of H. Lee Moffitt Cancer Center and Research Institute's 8 registered trials are currently recruiting — roughly 100% of the portfolio. A high recruiting share usually points to an active research pipeline with multiple programs at the enrollment stage.

H. Lee Moffitt Cancer Center and Research Institute's research footprint spans Metastatic Breast Cancer (1 trials), Breast Cancer (1), and Triple Negative Breast Cancer (1) as the top three conditions. The full condition list, sorted by trial count, is in the sidebar.

Phase 2 is the largest single phase in H. Lee Moffitt Cancer Center and Research Institute's portfolio at 38% of registered trials. The full phase breakdown appears in the sidebar.

Trials by H. Lee Moffitt Cancer Center and Research Institute

RECRUITINGPhase 2NCT06409390

Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer

The purpose of the study is to test a treatment strategy with currently approved drugs to see if it is practical to administer the available drugs in a new way that researchers...

Sponsor: H. Lee Moffitt Cancer Center and Research InstituteEnrolling: 151 location
Metastatic Breast Cancer
RECRUITINGPhase 1 / Phase 2NCT06238921

Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain...

This is a Phase I/II Study to determine the safety and efficacy of Sacituzumab Govitecan and Zimberelimab with stereotactic radiation (SRS) in participants with metastatic triple...

Sponsor: H. Lee Moffitt Cancer Center and Research InstituteEnrolling: 311 location
Breast CancerTriple Negative Breast Cancer
RECRUITINGPhase 1NCT06193486

Autologous Gamma Delta T Cells to Target Prostate Stem Cell Antigen in mCRPC

This is a phase 1 single center clinical trial for patients with end stage Metastatic Castration Resistant Prostate Cancer who have progressed through standard of care treatment...

Sponsor: H. Lee Moffitt Cancer Center and Research InstituteEnrolling: 301 location
Metastatic Castration-resistant Prostate Cancer
RECRUITINGEarly Phase 1NCT05080946

Using Aspirin to Improve Immunological Features of Ovarian Tumors

The purpose of the study is to evaluate the effectiveness of aspirin with neoadjuvant chemotherapy for decreasing markers of immune suppression in the tumor at interval debulking...

Sponsor: H. Lee Moffitt Cancer Center and Research InstituteEnrolling: 1004 locations
Ovarian CancerFallopian Tube CancerPeritoneal Cancer
RECRUITINGPhase 2NCT04562129

IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients

The purpose of this study is to find out if the administration of Interleukin-2 concurrently with ipilimumab followed by Nivolumab will result in improved anti-cancer activity and...

Sponsor: H. Lee Moffitt Cancer Center and Research InstituteEnrolling: 291 location
Melanoma Stage IIIMelanoma Stage IVInoperable Disease
RECRUITINGPhase 2NCT06144606

Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)

This is a Phase 2 Study is to determine the efficacy and safety rate of B-Cell Acute Lymphoblastic Leukemia (B-ALL) participants in remission with minimal residual disease (MRD)...

Sponsor: H. Lee Moffitt Cancer Center and Research InstituteEnrolling: 601 location
B-Cell Lymphoblastic LeukemiaAcute Lymphoblastic Leukemia
RECRUITINGPhase 1 / Phase 2NCT04923542

Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases

This is a single arm study of abemaciclib and endocrine therapy with stereotactic radiosurgery (SRS) among patients with hormone receptor (HR)+/HER2- metastatic breast cancer...

Sponsor: H. Lee Moffitt Cancer Center and Research InstituteEnrolling: 312 locations
Brain MetastasesHR+ Metastatic Breast Cancer
RECRUITINGNCT06745895

Multilevel Action Toward Colorectal Cancer and Hepatitis C Education and Screening

This innovative Multilevel Action Toward Colorectal Cancer (CRC) and Hepatitis C Virus (HCV) Education and Screening (MATCHES) intervention aims to promote concurrent HCV and CRC...

Sponsor: H. Lee Moffitt Cancer Center and Research InstituteEnrolling: 3501 location
Colorectal Cancer ScreeningHepatitis C Virus

How to Approach a Trial Listing

Each trial card above links to a dedicated page with the official ClinicalTrials.gov data plus a plain-English translation of the eligibility criteria. We translate technical terminology (ECOG performance status, hepatic function values, exclusionary lab thresholds) into language that a patient or caregiver can understand, but the original clinical text and the live ClinicalTrials.gov record always govern any actual eligibility decision.

Before contacting a trial site, write down questions for your treating physician using the framework on our 25 Questions guide. Discuss whether the trial fits your treatment plan, what the time commitment looks like, and whether your insurance will cover the standard-of-care portions. Trials are not a substitute for a treatment plan — they are an addition that needs medical guidance to evaluate.

Authoritative Resources

Verify any trial registration directly on ClinicalTrials.gov. For background on the FDA approval pathway that Phase 3 trials feed into, see the FDA drug approval process. For cancer-specific trial guidance, the National Cancer Institute publishes patient-oriented overviews. For global trial registrations beyond the U.S., the WHO ICTRP aggregates registries from around the world.

Frequently Asked Questions

How many clinical trials does H. Lee Moffitt Cancer Center and Research Institute have on ClinicalTrials.gov?

H. Lee Moffitt Cancer Center and Research Institute has 8 clinical trials registered on the federal ClinicalTrials.gov registry, of which 8 are actively recruiting participants right now. These counts come directly from the ClinicalTrials.gov API and are updated as the registry changes.

What conditions does H. Lee Moffitt Cancer Center and Research Institute study?

H. Lee Moffitt Cancer Center and Research Institute's registered trials cover 16 conditions on ClinicalTrials.gov, led by Metastatic Breast Cancer (1 trial), Breast Cancer (1 trial), Triple Negative Breast Cancer (1 trial), Metastatic Castration-resistant Prostate Cancer (1 trial), Ovarian Cancer (1 trial). The complete condition list appears in the sidebar of this page; each condition links to a page listing every recruiting trial in that area, regardless of sponsor.

How do I join a H. Lee Moffitt Cancer Center and Research Institute clinical trial?

Joining a clinical trial is a medical decision that should always involve your treating physician. Each trial page on this site includes the eligibility criteria translated into plain English alongside the official clinical text, plus the contact information that the sponsor has registered with ClinicalTrials.gov. Bring the trial information to your doctor before reaching out — they can review the full inclusion and exclusion criteria against your medical history and help you decide whether to pursue screening.

What does the trial phase mean?

Phase 1 trials test safety and dosing in small groups (often 20–80 healthy volunteers or patients). Phase 2 trials evaluate efficacy and side effects in larger groups (100–300 patients with the target condition). Phase 3 trials confirm efficacy and monitor safety in the largest groups (300–3,000+ patients) and form the basis of an FDA approval submission. Phase 4 studies happen after a treatment is approved, monitoring long-term safety and effectiveness in real-world use. Some trials register without a phase — common for device, behavioral, or observational studies.

Where does this trial data come from?

All trial data is pulled directly from the ClinicalTrials.gov API v2, the official federal trial registry maintained by the National Library of Medicine at NIH. Under FDAAA 801, most U.S. drug and device trials are required to register, making ClinicalTrials.gov the most comprehensive source. Sponsors are responsible for keeping their listings current; trial status can shift between data refreshes.

How This Sponsor Page Is Built

Every count on this page is derived directly from ClinicalTrials.gov API v2 records. Trial counts include all trials currently registered to this sponsor; the recruiting count reflects trials with status "Recruiting" or equivalent. Plain-English eligibility translations on each linked trial page preserve the original clinical text alongside an accessible version. Read the full methodology for the data pipeline and limitations.

Source: ClinicalTrials.gov API v2, maintained by the National Library of Medicine at NIH. Public domain. Cite as: "TrialFinderData. Data: ClinicalTrials.gov."

Medical disclaimer: This page is informational, not medical advice. Talk to your doctor about whether a clinical trial is right for you.

Last updated 2026-06-26 · 8 trials tracked for H. Lee Moffitt Cancer Center and Research Institute.